Troise C, Voltolini S, Canessa A, Pecora S, Negrini A C
Department of Allergology, Ospedale San Martino, Genova, Italy.
J Investig Allergol Clin Immunol. 1995 Jan-Feb;5(1):25-30.
A double-blind, placebo-controlled study of immunotherapy was conducted in 31 patients with allergic rhinitis due to Parietaria pollen to evaluate the efficacy and safety of high doses of allergen via the sublingual route. The patients were assessed before and after a 10-month period of treatment by clinical (symptom-medication scores and specific nasal reactivity) and immunological (total IgE, specific IgE, IgG and IgG4 antibodies) parameters. High doses of Parietaria extract corresponding to a cumulative dose of 105 BU for each patient were administered with negligible side effects. The actively treated patients had significantly lower medication scores than those on placebo (p < 0.05) when the maximum pollen count was recorded, and at the end of the trial they showed a significant decrease in nasal reactivity (p < 0.02) and a significant increase in serum specific IgG4 (p = 0.02). No differences were detected in any of these parameters in the placebo group. Possible explanations for the mechanisms of sublingual immunotherapy are proposed.
对31例因墙草花粉引起的变应性鼻炎患者进行了一项免疫疗法的双盲、安慰剂对照研究，以评估高剂量变应原经舌下途径给药的疗效和安全性。在为期10个月的治疗前后，通过临床（症状-用药评分和特异性鼻反应性）和免疫学（总IgE、特异性IgE、IgG和IgG4抗体）参数对患者进行评估。给予每位患者相当于105生物单位累积剂量的高剂量墙草提取物，副作用可忽略不计。在记录到最高花粉计数时，积极治疗的患者用药评分显著低于安慰剂组患者（p<0.05），并且在试验结束时，他们的鼻反应性显著降低（p<0.02），血清特异性IgG4显著升高（p = 0.02）。在安慰剂组的任何参数中均未检测到差异。文中提出了舌下免疫疗法作用机制的可能解释。
